Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis

Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A−) for all-cause mortality, cancer-specific mortality and r...

Full description

Bibliographic Details
Main Authors: Luchini, Claudio, Veronese, Nicola, Solmi, Marco, Cho, Hanbyoul, Kim, Jae-Hoon, Chou, Angela, Gill, Anthony J., Faraj, Sheila F., Chaux, Alcides, Netto, George J., Nakayama, Kentaro, Kyo, Satoru, Lee, Soo Young, Kim, Duck-Woo, Yousef, George M., Scorilas, Andreas, Nelson, Gregg S., Köbel, Martin, Kalloger, Steve E., Schaeffer, David F., Yan, Hai-Bo, Liu, Feng, Yokoyama, Yoshihito, Zhang, Xianyu, Pang, Da, Lichner, Zsuzsanna, Sergi, Giuseppe, Manzato, Enzo, Capelli, Paola, Wood, Laura D., Scarpa, Aldo, Correll, Christoph U.
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770758/
id pubmed-4770758
recordtype oai_dc
spelling pubmed-47707582016-03-21 Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis Luchini, Claudio Veronese, Nicola Solmi, Marco Cho, Hanbyoul Kim, Jae-Hoon Chou, Angela Gill, Anthony J. Faraj, Sheila F. Chaux, Alcides Netto, George J. Nakayama, Kentaro Kyo, Satoru Lee, Soo Young Kim, Duck-Woo Yousef, George M. Scorilas, Andreas Nelson, Gregg S. Köbel, Martin Kalloger, Steve E. Schaeffer, David F. Yan, Hai-Bo Liu, Feng Yokoyama, Yoshihito Zhang, Xianyu Pang, Da Lichner, Zsuzsanna Sergi, Giuseppe Manzato, Enzo Capelli, Paola Wood, Laura D. Scarpa, Aldo Correll, Christoph U. Research Paper Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A−) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS search from database inception until 01/31/2015 without language restriction was conducted, contacting authors for unpublished data. Eligible were prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of ARID1A (ARID1A+) vs. ARID1A−, assessed either via immunohistochemistry (loss of expression) or with genetic testing (presence of mutation). Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to ARID1A− adjusted for potential confounders. Of 136 hits, 25 studies with 5,651 participants (28 cohorts; ARID1A−: n = 1,701; ARID1A+: n = 3,950), with a mean follow-up period of 4.7 ± 1.8 years, were meta-analyzed. Compared to ARID1A+, ARID1A− significantly increased cancer-specific mortality (studies = 3; RR = 1.55, 95% confidence interval (CI) = 1.19–2.00, I2 = 31%). Using HRs adjusted for potential confounders, ARID1A− was associated with a greater risk of cancer-specific mortality (studies = 2; HR = 2.55, 95%CI = 1.19–5.45, I2 = 19%) and cancer recurrence (studies = 10; HR = 1.93, 95%CI = 1.22–3.05, I2 = 76%). On the basis of these results, we have demonstrated that loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders. For its role, this gene should be considered as an important potential target for personalized medicine in cancer treatment. Impact Journals LLC 2015-09-08 /pmc/articles/PMC4770758/ /pubmed/26384299 Text en Copyright: © 2015 Luchini et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Luchini, Claudio
Veronese, Nicola
Solmi, Marco
Cho, Hanbyoul
Kim, Jae-Hoon
Chou, Angela
Gill, Anthony J.
Faraj, Sheila F.
Chaux, Alcides
Netto, George J.
Nakayama, Kentaro
Kyo, Satoru
Lee, Soo Young
Kim, Duck-Woo
Yousef, George M.
Scorilas, Andreas
Nelson, Gregg S.
Köbel, Martin
Kalloger, Steve E.
Schaeffer, David F.
Yan, Hai-Bo
Liu, Feng
Yokoyama, Yoshihito
Zhang, Xianyu
Pang, Da
Lichner, Zsuzsanna
Sergi, Giuseppe
Manzato, Enzo
Capelli, Paola
Wood, Laura D.
Scarpa, Aldo
Correll, Christoph U.
spellingShingle Luchini, Claudio
Veronese, Nicola
Solmi, Marco
Cho, Hanbyoul
Kim, Jae-Hoon
Chou, Angela
Gill, Anthony J.
Faraj, Sheila F.
Chaux, Alcides
Netto, George J.
Nakayama, Kentaro
Kyo, Satoru
Lee, Soo Young
Kim, Duck-Woo
Yousef, George M.
Scorilas, Andreas
Nelson, Gregg S.
Köbel, Martin
Kalloger, Steve E.
Schaeffer, David F.
Yan, Hai-Bo
Liu, Feng
Yokoyama, Yoshihito
Zhang, Xianyu
Pang, Da
Lichner, Zsuzsanna
Sergi, Giuseppe
Manzato, Enzo
Capelli, Paola
Wood, Laura D.
Scarpa, Aldo
Correll, Christoph U.
Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
author_facet Luchini, Claudio
Veronese, Nicola
Solmi, Marco
Cho, Hanbyoul
Kim, Jae-Hoon
Chou, Angela
Gill, Anthony J.
Faraj, Sheila F.
Chaux, Alcides
Netto, George J.
Nakayama, Kentaro
Kyo, Satoru
Lee, Soo Young
Kim, Duck-Woo
Yousef, George M.
Scorilas, Andreas
Nelson, Gregg S.
Köbel, Martin
Kalloger, Steve E.
Schaeffer, David F.
Yan, Hai-Bo
Liu, Feng
Yokoyama, Yoshihito
Zhang, Xianyu
Pang, Da
Lichner, Zsuzsanna
Sergi, Giuseppe
Manzato, Enzo
Capelli, Paola
Wood, Laura D.
Scarpa, Aldo
Correll, Christoph U.
author_sort Luchini, Claudio
title Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
title_short Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
title_full Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
title_fullStr Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
title_full_unstemmed Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
title_sort prognostic role and implications of mutation status of tumor suppressor gene arid1a in cancer: a systematic review and meta-analysis
description Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A−) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS search from database inception until 01/31/2015 without language restriction was conducted, contacting authors for unpublished data. Eligible were prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of ARID1A (ARID1A+) vs. ARID1A−, assessed either via immunohistochemistry (loss of expression) or with genetic testing (presence of mutation). Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to ARID1A− adjusted for potential confounders. Of 136 hits, 25 studies with 5,651 participants (28 cohorts; ARID1A−: n = 1,701; ARID1A+: n = 3,950), with a mean follow-up period of 4.7 ± 1.8 years, were meta-analyzed. Compared to ARID1A+, ARID1A− significantly increased cancer-specific mortality (studies = 3; RR = 1.55, 95% confidence interval (CI) = 1.19–2.00, I2 = 31%). Using HRs adjusted for potential confounders, ARID1A− was associated with a greater risk of cancer-specific mortality (studies = 2; HR = 2.55, 95%CI = 1.19–5.45, I2 = 19%) and cancer recurrence (studies = 10; HR = 1.93, 95%CI = 1.22–3.05, I2 = 76%). On the basis of these results, we have demonstrated that loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders. For its role, this gene should be considered as an important potential target for personalized medicine in cancer treatment.
publisher Impact Journals LLC
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770758/
_version_ 1613544667971846144

Similar Items